Compare VEEV & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VEEV | INSM |
|---|---|---|
| Founded | 2007 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.5B | 41.2B |
| IPO Year | 2013 | 2000 |
| Metric | VEEV | INSM |
|---|---|---|
| Price | $224.43 | $177.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 27 | 21 |
| Target Price | ★ $299.92 | $185.84 |
| AVG Volume (30 Days) | 1.6M | ★ 3.7M |
| Earning Date | 11-20-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.69 | N/A |
| EPS | ★ 5.13 | N/A |
| Revenue | ★ $3,080,246,000.00 | $447,022,000.00 |
| Revenue This Year | $17.74 | $43.95 |
| Revenue Next Year | $12.24 | $130.35 |
| P/E Ratio | $43.79 | ★ N/A |
| Revenue Growth | 15.96 | ★ 30.34 |
| 52 Week Low | $201.54 | $60.40 |
| 52 Week High | $310.50 | $212.75 |
| Indicator | VEEV | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 32.92 | 40.56 |
| Support Level | $221.42 | $172.65 |
| Resistance Level | $225.78 | $179.33 |
| Average True Range (ATR) | 5.47 | 7.15 |
| MACD | 1.74 | -3.04 |
| Stochastic Oscillator | 38.22 | 37.18 |
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.